天益医疗2025年度权益分派实施公告详解
要点概览
- 公司以剔除回购股份后的总股本为基数，实施每10股转增4股及派发现金红利5元（含税）。
- 权益分派方案已于2026年5月15日通过年度股东大会审议。
- 权益分派实施后总股本将大幅增加，预计由58,947,368股增至81,609,395股。
- 分派基准日为2026年6月1日，除权除息日为6月2日。
- 涉税政策及持股期限影响实际派息金额，需投资者关注。
- 此公告涉及重大分红与转增，或对股价构成重要影响。
详细内容解读
一、权益分派方案核心内容
宁波天益医疗器械股份有限公司（天益医疗）2025年度股东大会审议通过了分红转增方案。本次权益分派以扣除公司回购专用证券账户中股份后的总股本56,655,068股为基数，每10股派发现金红利5.00元（含税），并以资本公积金每10股转增4股。回购股份2,292,300股不参与此次权益分派。
- 现金红利总额：28,327,534元（含税，具体金额以中国结算深圳分公司最终登记为准）。
- 转增股份总额：22,662,027股，转增后公司总股本将增至81,609,395股。
- 分派比例：每10股派5元现金并转增4股。
- 每10股折算现金红利：4.805563元。
- 每10股折算转增股份：3.844451股。
- 除权除息参考价计算公式：（除权除息日前一日收盘价-0.4805563元）/(1+0.3844451)。
二、对股东的影响及关键事项
- 本次权益分派涉及大比例转增和较高的现金分红，预计显著提升公司流通股本，对公司估值、流动性及未来资本运作有重要影响。
- 回购股份不参与分红转增，实际获益股东为在册流通股东。
- 分红实施后，公司2025年度每股净收益将因股本摊薄至-0.20元，需投资者关注公司未来盈利能力恢复情况。
- 税收政策复杂，个人投资者根据持股期限需补缴税款，证券投资基金及境外投资者适用不同税率。请投资者及时与券商或税务顾问核实实际到手金额。
- 本次权益分派方案经董事会、股东会审议通过，分派总金额固定，若分派前公司因回购、激励、再融资等导致股本变化，将按总分派额不变原则调整每股分派比例，具体以中国结算深圳分公司登记结果为准。
- 登记日为2026年6月1日，除权除息日为6月2日，权益登记当天下午收市后持有股份的投资者可获得此次分红转增。
三、分红派发和咨询方式
- 大部分A股股东的现金红利将由中国结算深圳分公司代为划入证券账户。
- 部分特定股东将由公司自行派发现金红利。
- 咨询地址为浙江省宁波市东钱湖旅游度假区新业路1号，联系人李孟良，联系电话0574-55011010。
四、投资者需重点关注的风险点及潜在影响
- 大比例转增股本：公司总股本显著增加，未来每股收益将被摊薄，若盈利能力不能同步增长，或对股价构成压力。
- 高现金分红：短期内有助于提升股东回报，吸引分红型投资者。
- 税务影响：持股期限不同者实际红利到账金额不同，需特别关注。
- 除权除息价格调整：高比例转增和现金分红将影响除权除息后的股价表现，需合理预期。
- 本次权益分派为公司2025年度重要资本事件，可能对二级市场股价产生较大影响。
免责声明：本文内容根据天益医疗2025年度权益分派实施公告整理，仅供投资者参考，不构成任何投资建议。投资有风险，决策需谨慎。
English Version
Detailed Analysis: Tianyi Medical 2025 Annual Equity Distribution Implementation Announcement
Key Highlights
- The company will distribute cash dividends of RMB 5 (tax included) and grant 4 bonus shares for every 10 shares, based on the total shares excluding repurchased shares.
- The equity distribution proposal was approved at the annual shareholders’ meeting on May 15, 2026.
- After the distribution, total share capital will increase significantly from 58,947,368 to 81,609,395 shares.
- Record date is June 1, 2026, and ex-dividend/ex-rights date is June 2, 2026.
- Tax policies and holding period will affect the actual dividend received; investors should pay attention.
- This announcement involves significant bonus issues and dividends, which may have a material impact on the share price.
In-depth Details
1. Core Content of the Equity Distribution Plan
Ningbo Tianyi Medical Devices Co., Ltd. (Tianyi Medical) announced that the 2025 annual shareholders’ meeting has approved a bonus issue and cash dividend plan. Based on the total shares after deducting repurchased shares (56,655,068 shares), a cash dividend of RMB 5.00 (tax included) per 10 shares will be distributed, alongside a 4-for-10 bonus share issue from the capital reserve. The 2,292,300 repurchased shares will not participate.
- Total cash dividend: RMB 28,327,534 (tax included, subject to final registration with China Securities Depository and Clearing Corporation Shenzhen Branch).
- Total bonus shares: 22,662,027 shares. After the bonus issue, total share capital will increase to 81,609,395 shares.
- Distribution ratio: RMB 5 cash + 4 bonus shares for every 10 shares.
- Per 10 shares, calculated cash dividend: RMB 4.805563.
- Per 10 shares, calculated bonus shares: 3.844451 shares.
- Ex-dividend/reference price formula: (Closing price before ex-date – 0.4805563 RMB)/(1+0.3844451).
2. Impact on Shareholders and Key Points
- The high-ratio bonus issue and significant cash dividend are expected to substantially increase the company’s tradable shares, impacting valuation, liquidity, and future capital operations.
- Repurchased shares do not participate, so the benefit goes to registered shareholders only.
- After the distribution, the 2025 EPS will be diluted to -0.20 RMB; investors should monitor the company’s profitability recovery closely.
- Tax policies are complex. Individual investors will need to pay additional taxes based on holding period. Different rates apply for funds and overseas investors. Please consult your broker or tax advisor for details.
- The plan has been approved by the board and shareholders’ meeting. If share capital changes before execution (due to repurchase, incentive, refinancing, etc.), the per-share ratio will be adjusted but the total distribution amount remains unchanged.
- Record date is June 1, 2026. Ex-dividend/ex-rights date is June 2, 2026. Shareholders on record at market close on the record date are eligible.
3. Dividend Distribution & Enquiry Channel
- Most A-share holders will receive cash dividends via China Securities Depository and Clearing Corporation Shenzhen Branch directly into their securities account.
- Certain shareholders will receive payment directly from the company.
- Enquiry address: No. 1 Xinye Road, Dongqian Lake Tourism Resort, Ningbo, Zhejiang. Contact: Li Mengliang, Tel: 0574-55011010.
4. Risk Points & Potential Impact for Investors
- Substantial bonus issue: Total share capital increases significantly, diluting EPS. If profitability does not improve, there may be downward pressure on the share price.
- High cash dividend: This may attract dividend-focused investors in the short term.
- Tax impact: Actual dividend received depends on holding period and investor type.
- Ex-dividend price adjustment: The significant bonus issue and cash dividend will affect post-ex price performance; set expectations accordingly.
- This equity distribution is a major event and may have a significant impact on market price.
Disclaimer: This article is based on the Tianyi Medical 2025 Annual Equity Distribution Implementation Announcement and is intended for informational purposes only. It does not constitute investment advice. Investment involves risk. Please make decisions prudently.
